Table 1.

Baseline characteristics of six trials comparing PD-1 inhibitors to chemotherapy or everolimus

Study	Phase	Underlying malignancy	Treatment arm	Control arm	Treatment arm	Control arm	CTC version	Jadad score
Borghaei et al9	III	NSCLC	Nivolumab 3 mg/kg every 2 weeks	Docetaxel	287	268	4.0	3
Brahmer et al10	III	NSCLC	Nivolumab 3 mg/kg every 2 weeks	Docetaxel	131	129	4.0	3
Robert et al25	III	Melanoma	Nivolumab 3 mg/kg every 2 weeks	Dacarbazine	206	205	4.0	5
Weber et al7	III	Melanoma	Nivolumab 3 mg/kg every 2 weeks	Investigator’s choice of chemotherapy	268	102	4.0	3
Motzer et al11	III	RCC	Nivolumab 3 mg/kg every 2 weeks	Everolimus	406	397	4.0	3
Herbst et al5	II/III	NSCLC	Pembrolizumab 2 mg/kg every 3 weeks	Docetaxel	339	309	4.0	3
			Pembrolizumab 10 mg/kg every 3 weeks	Docetaxel	343

Abbreviations: PD-1, program death 1; CTC, common toxicity criteria; NSCLC, non-small-cell lung cancer; RCC, renal cell carcinoma.